Murdock Hunter R. 4

What Happened

• Murdock Hunter, General Counsel of Axsome Therapeutics (AXSM), was granted 16,385 restricted stock units (RSUs) on February 26, 2026. The Form 4 reports the award as a derivative acquisition at $0.00 per unit (transaction code A).
• Each RSU represents a contingent right to one share of Axsome common stock (footnote F1). There is no immediate cash purchase or sale — this is a compensation grant, not an open-market trade.

Key Details

• Transaction date: 2026-02-26; Form 4 filed 2026-02-27 (timely; Form 4 due within two business days).
• Grant size: 16,385 RSUs; reported price: $0.00 per unit (derivative award).
• Shares owned after transaction: Not disclosed in the filing.
• Vesting and delivery (footnote F2): 25% vests on the one‑year anniversary of the grant; the remainder vests in three substantially equal annual installments so the RSUs are fully vested by February 26, 2030. Vested shares will be delivered upon the earlier of (i) a Change in Control, (ii) the reporting person’s separation of service (including various termination scenarios), or (iii) seven years from the grant date.
• No 10b5-1 plan, tax-withholding sale, or cashless exercise reported.

Context

• RSUs are a common form of equity compensation; they do not represent immediate ownership of shares until vested and delivered. This grant is routine executive compensation rather than an outright market purchase or sale.
• Because the filing shows an award (not a sale), it should not be interpreted as a bearish signal. Tax events and actual share issuance occur later when RSUs vest and are delivered per the plan terms.